Terms: = Breast cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
181 results:
1. Is the QCI framework suited for monitoring outcomes and costs in a teaching hospital using value-based healthcare principles? A retrospective cohort study.
van Veghel W; van Dijk SC; Klem TM; Weel AE; Bügel JB; Birnie E
BMJ Open; 2024 May; 14(5):e080257. PubMed ID: 38692726
[TBL] [Abstract] [Full Text] [Related]
2. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
3. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
4. Non-medical interventions to enhance return to work for people with cancer.
de Boer AG; Tamminga SJ; Boschman JS; Hoving JL
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD007569. PubMed ID: 38441440
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
6. Patient survey on cancer genomic medicine in Japan under the national health insurance system.
Kage H; Akiyama N; Chang H; Shinozaki-Ushiku A; Ka M; Kawata J; Muto M; Okuma Y; Okita N; Tsuchihara K; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Yachida S; Hirasawa A; Kubo M; Kenmotsu H; Tanabe M; Ushiku T; Muto K; Seto Y; Oda K
Cancer Sci; 2024 Mar; 115(3):954-962. PubMed ID: 38273803
[TBL] [Abstract] [Full Text] [Related]
7. Racial disparities in surgical outcomes after mastectomy in 223 000 female breast cancer patients: a retrospective cohort study.
Knoedler S; Kauke-Navarro M; Knoedler L; Friedrich S; Matar DY; Diatta F; Mookerjee VG; Ayyala H; Wu M; Kim BS; Machens HG; Pomahac B; Orgill DP; Broer PN; Panayi AC
Int J Surg; 2024 Feb; 110(2):684-699. PubMed ID: 38052017
[TBL] [Abstract] [Full Text] [Related]
8. breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract] [Full Text] [Related]
9. Research progress on tamoxifen and its analogs associated with nuclear receptors.
Dong N; Du Y; Zheng Y; Zhang H; Lv H; Yan Z
Future Med Chem; 2023 Aug; 15(15):1427-1442. PubMed ID: 37706220
[TBL] [Abstract] [Full Text] [Related]
10. EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217/SOS1 axis to facilitate breast cancer progression.
Ju C; Zhou M; Du D; Wang C; Yao J; Li H; Luo Y; He F; He J
Cell Death Dis; 2023 Aug; 14(8):559. PubMed ID: 37626035
[TBL] [Abstract] [Full Text] [Related]
11. Successful breast Conservation After Neoadjuvant Chemotherapy in Lobular breast cancer: The Role of Menopausal Status in Response to treatment.
Ramalingam K; Clelland E; Rothschild H; Mujir F; Record H; Kaur M; Mukhtar RA
Ann Surg Oncol; 2023 Nov; 30(12):7099-7106. PubMed ID: 37561345
[TBL] [Abstract] [Full Text] [Related]
12. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract] [Full Text] [Related]
13. Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.
Xia W; Chen W; Ni C; Meng X; Wu J; Yang Q; Tang H; Yuan H; Fang S
Breast Cancer Res; 2023 Jul; 25(1):85. PubMed ID: 37461019
[TBL] [Abstract] [Full Text] [Related]
14. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.
Skafida E; Andrikopoulou A; Terpos E; Markellos C; Moustafa S; Pectasides D; Dimopoulos MA; Zagouri F; Vassilopoulos D
Breast J; 2023; 2023():3614296. PubMed ID: 37293258
[TBL] [Abstract] [Full Text] [Related]
15. Risk factors for seroma formation after axillary lymph node dissection with special focus on the impact of early shoulder exercise.
Borg G; Dihge L; Johansson K
Acta Oncol; 2023 May; 62(5):444-450. PubMed ID: 37129993
[TBL] [Abstract] [Full Text] [Related]
16. What do we know about the psychosocial issues associated with cancer during pregnancy? A scoping review and gap analysis.
Harris J; Ream E; Armes J; Gibson F; Marcu A; Parsons CT; Robinson A; Varghese S; Poole K
BMJ Open; 2023 Mar; 13(3):e063283. PubMed ID: 36868601
[TBL] [Abstract] [Full Text] [Related]
17. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
Lowry KP; Ichikawa L; Hubbard RA; Buist DSM; Bowles EJA; Henderson LM; Kerlikowske K; Specht JM; Sprague BL; Wernli KJ; Lee JM
Cancer; 2023 Apr; 129(8):1173-1182. PubMed ID: 36789739
[TBL] [Abstract] [Full Text] [Related]
18. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
[TBL] [Abstract] [Full Text] [Related]
19. Development of hyaluronic acid-anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer.
Jain D; Yadav AK
Drug Deliv Transl Res; 2023 Jun; 13(6):1730-1744. PubMed ID: 36641487
[TBL] [Abstract] [Full Text] [Related]
20. The majority of 922 prediction models supporting breast cancer decision-making are at high risk of bias.
Hueting TA; van Maaren MC; Hendriks MP; Koffijberg H; Siesling S
J Clin Epidemiol; 2022 Dec; 152():238-247. PubMed ID: 36633901
[TBL] [Abstract] [Full Text] [Related]
[Next]
